Prostate cancer: PARP inhibitors in prostate cancer

COR2ED Medical Education: Dr Jason Alcorn, nurse consultant for Uro-Oncology & Andrology at the Mid Yorkshire Hospitals NHS Trust, United Kingdom and Dr Alicia Morgans, Genitourinary Medical Oncologist and Medical Director of the Survivorship Program at the Dana-Farber Cancer Institute in the United States, discuss 'PARP inhibitors in prostate cancer: Management of adverse events and the importance of communication with patients’ as part of the GU NURSES CONNECT podcast series covering ‘PARP inhibitors in prostate cancer’.

In this podcast, the experts discuss adverse events associated with PARP inhibitors and the management of them, in particular thrombocytopenia, gastrointestinal effects and fatigue. Jason provides some insight into how nurses support and communicate with patients, the importance of early reporting of side effects and how to manage these. Finally, the ongoing trials of PARP inhibitors in combination with other prostate cancer treatments are also considered and what these trials may mean for patients.